These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 8969327)
1. Current efforts in standards development. United States. Power EJ Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327 [No Abstract] [Full Text] [Related]
2. The real world calls. Evolving operationalization of standards by users. Med Care; 1996 Dec; 34(12 Suppl):DS173-5. PubMed ID: 8999204 [No Abstract] [Full Text] [Related]
3. Accumulating evidence for the case of differential discounting. Postma MJ; Parouty M; Westra TA Expert Rev Clin Pharmacol; 2013 Jan; 6(1):1-3. PubMed ID: 23272787 [No Abstract] [Full Text] [Related]
4. The role of the pharmaceutical industry in drug development in dermatology. Cauwenbergh G Clin Dermatol; 2002; 20(5):467-73. PubMed ID: 12435516 [No Abstract] [Full Text] [Related]
5. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. Mullahy J Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321 [No Abstract] [Full Text] [Related]
6. Pharmacoeconomics comes of age? Walley T; Breckenridge A Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057 [TBL] [Abstract][Full Text] [Related]
8. Industry responsibility in interactive computer modeling. Mauskopf J Med Care; 1996 Dec; 34(12 Suppl):DS165-72. PubMed ID: 8969323 [No Abstract] [Full Text] [Related]
9. Transparency of economic evaluations of health technologies. Rovira J Pharmacoeconomics; 2008; 26(3):181-3. PubMed ID: 18282013 [No Abstract] [Full Text] [Related]
10. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals. Luce BR Pharmacoeconomics; 1993 Jan; 3(1):1-9. PubMed ID: 10146982 [No Abstract] [Full Text] [Related]
11. Initial development of the Australian Guidelines. Freund DA Med Care; 1996 Dec; 34(12 Suppl):DS211-5. PubMed ID: 8969328 [No Abstract] [Full Text] [Related]
12. The proper role for discounting. Search in progress. Lipscomb J Med Care; 1996 Dec; 34(12 Suppl):DS119-23. PubMed ID: 8969320 [No Abstract] [Full Text] [Related]
13. Perspective and pharmacoeconomic analyses. Kozma CM Manag Care Interface; 2005 Dec; 18(12):53-4. PubMed ID: 16405225 [No Abstract] [Full Text] [Related]
14. Pharmacoeconomics: integrating economic evaluation into clinical trials. Haycox A; Drummond M; Walley T Br J Clin Pharmacol; 1997 Jun; 43(6):559-62. PubMed ID: 9205814 [No Abstract] [Full Text] [Related]
15. Cost effectiveness and cost-savings opportunities associated with human growth hormone. Manag Care Interface; 2005; Suppl():14-5. PubMed ID: 16268200 [No Abstract] [Full Text] [Related]
16. Update and evaluation of Australian guidelines. Government perspective. Mitchell A Med Care; 1996 Dec; 34(12 Suppl):DS216-25. PubMed ID: 8969329 [No Abstract] [Full Text] [Related]
17. How can pharmacoeconomics be more useful? Kozma CM Manag Care Interface; 2005 May; 18(5):25-6. PubMed ID: 15941186 [No Abstract] [Full Text] [Related]
18. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Postma MJ; Boersma C; Gansevoort RT Nephrol Dial Transplant; 2008 Apr; 23(4):1103-6. PubMed ID: 17210586 [No Abstract] [Full Text] [Related]
19. Pharmaceutical research: cost savings through innovation. Cohen KR; Levy RA AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463 [No Abstract] [Full Text] [Related]